Effect Of Lipoprotein Apheresis On PCSK9 Levels
Dr. B. Hohenstein
Division of Nephrology
Head Extrakorporeal Treatment and Lipoprotein Apheresis Center , Germany


Proprotein convertase subtilisin/kexin type 9, also known as PCSK9, is an enzyme produced in the liver. PCSK9 binds to the LDL receptor (LDLR) and increases the degradation of the LDLR. This results in the decreased metabolism of LDL-C, which leads to hypercholesterolemia.

Multiple pharmaceutical companies have recently developed an antibody to PCSK9. This drug, which is still in phase III trials, can lower LDL-C by an additional 70%  to patients who are already taking a statin drug.

During the ISFA Congress we will have Dr. Bernd Hohenstein discuss the changes that occur to PCSK9 plasma levels following Lipoprotein-apheresis. Additionally, Dr. Patrick M. Moriarty will discuss the protocol design for the ESCAPE Trial, a multi-center and 2 nation trial examining the effects of adding PCSK9 antibodies to the plasma levels of LDL-C to heterzygous Familial Hypercholesterolemia patients receiving regular Lipoprotein-apheresis therapy.

Click Here to view the preliminary program.

Current Status And Future Perspectives Of Lp(A) Apheresis
Dr. Beate R. Jaeger, Germany


Lipoprotein a [Lp(a)] is a plasma lipoprotein composed of a low density lipoprotein (LDL) core and apolipoprotein B-100 (ApoB) to which apolipoprotein(a) is attached via a disulfide bond. Lp(a) possesses atherogenic, inflammatory, and thrombogenic properties, which have been shown through epidemiological, meta-analyses, mendelian randomization and genome association to contribute to an increased risk for cardiovascular disease (CVD). Lp(a) levels are relatively unaffected by changes in diet or use of the most commonly prescribed lipid-lowering medications.

During the ISFA Congress we will have a discussion by Dr. Beate R. Jaeger on the ability of Lipoprotein-apheresis to lower plasma levels of Lp(a) and CVD. Additionally, Dr. Sam Tsimakas from UCSD and ISISI Pharmaceuticals will present recent data on antisense therapy’s ability to lower Lp(a) by 90%.

Click Here to view the preliminary program.

The role of Apheresis in the treatment of Ebola Virus Disease
Anne Winkler
Emory University, USA


Ebola virus causes a severe and often fatal hemorrhagic fever resulting in over 10,000 deaths during 2013-2015 in West Africa. Currently no specific therapy is available that efficiently treats the disease. Of promise is a human monoclonal antibody which may be useful in vaccine development.

Present therapy includes replacement of coagulation factors or heparin if DIC develops and supportive care. Convalescent plasma therapy (CPT) is an old fashioned therapy which was used for diphtheria and tetanus. Recently, CPT has been implemented for emerging infections, which do not have any remedies, such as avian influenza, SARS, and the Ebola virus.

At this year’s ISFA Congress we have Dr. Anne Winkler who is an expert in the field of CPT for patients with the Ebola virus. She will present the most recent data on the methods and success of this treatment.

Click Here to view the preliminary program.